Literature DB >> 22211277

Long-term survival, autonomy, and quality of life of elderly patients undergoing aortic valve replacement.

Sílvia Marta Oliveira1, Ana Sofia Correia, Mariana Paiva, Alexandra Gonçalves, Marta Pereira, Elisabete Alves, Paula Dias, Rui Almeida, Armando Abreu, Paulo Pinho.   

Abstract

AIMS: We reviewed the long-term survival, autonomy, and quality of life (QoL) of elderly patients undergoing aortic valve replacement (AVR).
METHODS: Records of patients ≥75 years old that underwent AVR from 2002 to 2006 were retrospectively analyzed. Functional status was classified with Barthel Index (BI). QoL was presumed as the self-perception of well-being after AVR. Independent predictors of mortality were identified using the Cox proportional hazards model.
RESULTS: We included 114 patients, with a mean age of 78.5 ± 2.5 years. Seventy (59.8%) patients were females. Mean additive and logistic EuroSCORE were 7 ± 2 and 9 ± 7, respectively. Follow-up on vital status was achieved for 113 (99.1%) patients after a mean period of 47.2 ± 23.4 months. Twenty-seven (23.7%) patients died (including three operative deaths). Survival up to one, three, and five years of follow-up was 94.4%, 86.7%, and 76.1%, respectively. Multivariate analysis showed that pulmonary hypertension and diabetes were independent predictors of all-cause mortality. Information on BI score and QoL was obtained for 77 (89.5%) and patients. Among those, 69 (89.6%) were autonomous according to BI and 72 (93.5%) considered having had an improvement in QoL.
CONCLUSION: Patients ≥75 years old undergoing AVR presented good medium-term survival. Predictors of an adverse outcome were significant pulmonary hypertension and diabetes. At follow-up, most achieved improvement of QoL and remained autonomous. These results stress that excellent long-term outcomes with AVR can be achieved in appropriately selected elderly patients.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22211277     DOI: 10.1111/j.1540-8191.2011.01360.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  4 in total

1.  Prognostic value of tricuspid regurgitation velocity and probability of pulmonary hypertension in patients undergoing transcatheter aortic valve implantation.

Authors:  Pawel Kleczynski; Artur Dziewierz; Agata Wiktorowicz; Maciej Bagienski; Lukasz Rzeszutko; Danuta Sorysz; Jaroslaw Trebacz; Robert Sobczynski; Marek Tomala; Dariusz Dudek
Journal:  Int J Cardiovasc Imaging       Date:  2017-07-01       Impact factor: 2.357

2.  Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry.

Authors:  Derk Frank; Simon Kennon; Nikolaos Bonaros; Mauro Romano; Thierry Lefèvre; Carlo Di Mario; Pierluigi Stefàno; Flavio Luciano Ribichini; Dominique Himbert; Marina Urena-Alcazar; Jorge Salgado-Fernandez; Jose Joaquin Cuenca Castillo; Bruno Garcia; Jana Kurucova; Martin Thoenes; Claudia Lüske; Peter Bramlage; Rima Styra
Journal:  Open Heart       Date:  2019-05-21

Review 3.  Evaluating treatment-specific post-discharge quality-of-life and cost-effectiveness of TAVR and SAVR: Current practice & future directions.

Authors:  Maximilian A Fliegner; Devraj Sukul; Michael P Thompson; Nirav J Shah; Reza Soroushmehr; Jeffrey S McCullough; Donald S Likosky
Journal:  Int J Cardiol Heart Vasc       Date:  2021-09-06

4.  Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies.

Authors:  Farid Foroutan; Gordon H Guyatt; Kathleen O'Brien; Eva Bain; Madeleine Stein; Sai Bhagra; Daegan Sit; Rakhshan Kamran; Yaping Chang; Tahira Devji; Hassan Mir; Veena Manja; Toni Schofield; Reed A Siemieniuk; Thomas Agoritsas; Rodrigo Bagur; Catherine M Otto; Per O Vandvik
Journal:  BMJ       Date:  2016-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.